During AAO, a number of communications - posters, presentations and debates - will report on the large amount of ocriplasmin real world clinical data gathered since its first introduction in 2013, as well as on the outcome of the OASIS study, a 2-year randomized, sham-controlled trial evaluating efficacy and safety of ocriplasmin in 220 patients.
'Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial' was published in the latest issue of Ophthalmology, the official AAO Journal.
The AAO meeting, which is taking place in Chicago from 15-18 October, is the largest ophthalmology meeting in the world with more than 24,000 people expected to attend. ThromboGenics data presentations will also be part of the Retina Subspecialty Day meetings which will take place on 14th October and precede AAO.
To date, over 25,000 patients have been treated with ocriplasmin for the treatment of their symptomatic vitreomacular adhesion and/or vitreomacular traction.
ThromboGenics will be exhibiting at AAO (booth #1272) and during the Subspecialty Day meeting (booth #80) where attendees will be welcomed and have the opportunity to discuss the company's next clinical developments in the area of disease modifying compounds for diabetic eye disease.
Dr Patrik De Haes, CEO of ThromboGenics, comments: "The AAO meeting offers a great opportunity for ThromboGenics to showcase our research and commitment to the global retina community it serves. We are always excited to attend AAO and related meetings, as we strive to advance our research and clinical development in diabetic eye disease."
For further information about the AAO meeting please visit www.aao.org/annual-meeting
For further information please contact:
Global Head of Corporate Communications & IR
+32 16 75 13 10 / +32 478 33 56 32
Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
Tel: +44 20 7282 2867
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease.
The company's attractive pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market. ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial to assess THR-409 (ocriplasmin) as a potential treatment to prevent the patients with non-proliferative diabetic retinopathy progress to proliferative diabetic retinopathy. THR-317, a PIGF inhibitor being developed to treat diabetic macular edema, or as a combination therapy with anti-VEGF treatments, is expected to enter the clinic by year end 2016. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Alcon (Novartis) commercializes JETREA® outside the United States.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.
More information is available at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.